BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524516

BACPHAR

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

BACIL PHARMA LTD. Share Price Update

As of the latest trading session, BACIL PHARMA LTD. share price is currently at ₹ 36.36, which is down by ₹ -1.91 from its previous closing. Today, the stock has fluctuated between ₹ 36.36 and ₹ 36.36. Over the past year, BACIL PHARMA LTD. has achieved a return of -10.41 %. In the last month alone, the return has been -8.24 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

BACIL PHARMA LTD. fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    52.20

  • P/E Ratio (TTM)

    49.70

  • Beta

    -0.01

  • Book Value / share

    17.98

  • Return on equity

    -0.98%

  • EPS (TTM)

    0.77

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    0.67

info icon alternate text

BACIL PHARMA LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.11
Net Profit 0.67
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.48
EBITDA 0.89
Effective Tax Rate (%) 24.71
Particulars MAR 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.07
Net Profit 0.02
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.03
EBITDA 0.02
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.06
Net Profit -0.06
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.10
EBITDA -0.06
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.07
Net Profit 0.48
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.82
EBITDA 0.49
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.04
Net Profit -0.03
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.06
EBITDA -0.03
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.25
Net Profit 0.40
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.69
EBITDA 0.41
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.19
Net Profit -0.06
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.10
EBITDA -0.06
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 0.00
Operating Expense 0.22
Net Profit -0.10
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.17
EBITDA -0.10
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 0.00
Operating Expense 3.92
Net Profit -3.86
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -6.55
EBITDA -3.86
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 0.00
Operating Expense 0.31
Net Profit -0.24
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.41
EBITDA -0.24
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 18.20
ROE % -0.98
ROCE % -1.04
Total Debt to Total Equity 0.01
EBITDA Margin 0.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1.86
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.05
EBITDA Margin 0.00
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1.68
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.02
EBITDA Margin 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1.88
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.08
EBITDA Margin 0.00
Particulars MAR 2021 (Values in Cr)
Book Value / Share 2.13
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.13
EBITDA Margin 0.00
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.85
Total Assets 25.60
Total Liabilities 25.60
Total Equity 25.43
Share Outstanding 14353000
Price to Book Ratio 2.33
Return on Assets (%) 1.57
Return on Capital (%) 1.58
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.04
Total Assets 1.32
Total Liabilities 1.32
Total Equity 1.21
Share Outstanding 5890000
Price to Book Ratio 7.87
Return on Assets (%) -4.45
Return on Capital (%) -4.5
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 1.12
Total Liabilities 1.12
Total Equity 1.09
Share Outstanding 5890000
Price to Book Ratio 3.26
Return on Assets (%) -9.03
Return on Capital (%) -9.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.22
Total Assets 1.27
Total Liabilities 1.27
Total Equity 1.22
Share Outstanding 5890000
Price to Book Ratio 3.05
Return on Assets (%) -303.54
Return on Capital (%) -306.94
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 4.08
Total Liabilities 4.08
Total Equity 1.39
Share Outstanding 5890000
Price to Book Ratio 1.46
Return on Assets (%) -5.85
Return on Capital (%) -15.27
Particulars MAR 2025 (Values in Cr)
Net Income 0.40
Cash from Operations 0.40
Cash from Investing 0.33
Cash from Financing 2.07
Net change in Cash 2.81
Free Cash Flow 0.40
Particulars MAR 2024 (Values in Cr)
Net Income -0.05
Cash from Operations 0.00
Cash from Investing 0.07
Cash from Financing -0.06
Net change in Cash 0.01
Free Cash Flow 0.00
Particulars MAR 2023 (Values in Cr)
Net Income -0.10
Cash from Operations -0.14
Cash from Investing -0.11
Cash from Financing 0.06
Net change in Cash -0.20
Free Cash Flow -0.14
Particulars MAR 2022 (Values in Cr)
Net Income -3.86
Cash from Operations -4.00
Cash from Investing 3.81
Cash from Financing 0.32
Net change in Cash 0.13
Free Cash Flow -4.00
Particulars MAR 2021 (Values in Cr)
Net Income -0.23
Cash from Operations -0.39
Cash from Investing 0.52
Cash from Financing -0.07
Net change in Cash 0.05
Free Cash Flow -0.39
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 32.54 13.28 1.78 249.36 30.00 / 68.00
BLISS GVS PHARMA LTD 152.15 15.08 1.53 1607.46 105.05 / 190.65
CIPLA LTD 1580.75 23.68 4.09 127687.56 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 262.85 7.40 2.13 773.59 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2641.95 47.26 22.93 44756.23 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 32.54 17.68 5.14 249.36 30.00 / 68.00
AMRUTAJAN HEALTH LTD 743.40 39.42 6.58 2149.22 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9338.45 110.40 30.30 23346.13 6222.35 / 10653.05
BLISS GVS PHARMA LTD 152.15 22.78 1.51 1607.46 105.05 / 190.65

BACIL PHARMA LTD. shareholding pattern

Holding

Others
99.91%
Promoter Holdings
0.08%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Nikita Hiren Patel 2790000.0 (19.44%) Public Shareholding
Manubhai Amrutlal Shah 2627000.0 (18.3%) Public Shareholding
Gb Hospitality India 2075000.0 (14.46%) Public Shareholding
Manmohan Jagdishprasad Ghuwalewala 600000.0 (4.18%) Public Shareholding
Navin Keshrimal Mehta 311801.0 (2.17%) Public Shareholding
Vicky Pratapbhai Shah 306695.0 (2.14%) Public Shareholding
Chhaya Gaurang Shah 259799.0 (1.81%) Public Shareholding
Deepa Navin Mehta 250000.0 (1.74%) Public Shareholding
Saroj Kishor Mehta 165861.0 (1.16%) Public Shareholding
Dhrumil Rakesh Patel 157488.0 (1.1%) Public Shareholding
Gulecha Investment & Trading Co Pvt Ltd 10800.0 (0.08%) Shareholding of Promoter and Promoter Group
Sub Total A2 11000.0 (0.08%) Shareholding of Promoter and Promoter Group
Khem Sum Apparels Overseas Limited 200.0 (0.0%) Shareholding of Promoter and Promoter Group
Suman P Shah 500.0 (0.0%) Shareholding of Promoter and Promoter Group

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

BACIL PHARMA LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
36.36 -4.99 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 39.70
  • 26 Days 40.90
  • 10 Days 40.50
  • 50 Days 40.80
  • 12 Days 40.70
  • 100 Days 40.90
  • 20 Days 41.00
  • 200 Days 38.10
38.51 PIVOT

First Support

38.03

First Resistance

38.76

Second Support

37.78

Second Resistance

39.24

Third Support

37.30

Third Resistance

39.49

RSI

41.36

ADX

17.24

MACD

-0.20

Williams % R

-89.93

Commodity Channel Index (CCI)

-164.55

Date

2025-10-29

Week

135156.00

Same Day

197050.00

Month

35962.00

1 Year

-0.01

3 Year

-0.39

Over 1 Month

-8.24%

down

Over 1 Year

-10.41%

down

Over 3 Months

1.83%

down

Over 3 Years

69.77%

down

Over 6 Months

-5.66%

down

Over 5 Years

45.84%

down

BACIL PHARMA LTD. Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

BACIL PHARMA LTD. Share Price

Incorporated as a private limited company in Maharashtra in May '87, Bacil Pharma (BPL) was converted into a public limited company in Oct.'90. The main business activity of the Company is Pharmaceutical.

Bal Pharma is a fully integrated and leading Indian pharmaceutical company specialized in Prescription drugs, Branded Formulations, APIs, Generic & OTC products, Intravenous Infusions and Bulk Drugs. Domestic operations are spread across pan India. The company has strong field force of 500 plus, spread over various States and Districts. It has a strong distribution set up, with Super Stockist in all the States and stockists for retail coverage. To augment the domestic market, Company's operations are based on focused approach.

Multi-Speciality division Vibrant specialises in various specialties, like Anti-Infectives, Pain Management, Respiratory Care, Women's Health, to name a few. Aziwin, Ebay, Balvibe, MNF, Ocium and Monogesic Plus Gel (Innovative Pain Relieving Gel, first time in India) are some of the leading brands in the respective segments. Bal Vedics Division integrates modern medicine with herbal/ayurvedic preparation targeting specific conditions like, Prostrate Enlargement, Renal Calculi, Male Infertility, Women Health etc. Bal Pharma Institutional division is associated with the top Government bodies and Hospitals to extend its product range to the masses. Every area is well covered and supplied through there channel partners.

Bal Pharma Unit - 1, is a finished dosage facility for manufacturing Tablets and Capsules. Bal Pharma Unit - 2, is involved in the manufacturing of APIs. A well-equipped R&D laboratory, a good Kilo laboratory and quality control facilities form the other spheres of activity here. Bal Pharma Unit - 3, is a finished dosage facility for manufacturing Intravenous Fluids, Ophthalmic Preparations & Liquid Oral Preparations.

BPL came out with a public issue of Rs 7 cr in Mar.'94 to set up a plant at Vapi to manufacture bulk drugs like atenalol, norfloxacin, pefloxacin and ciprofloxacin.

The company entered into a marketing arrangement with a distributor Kam Han Industries, Hong Kong, to export 50% of the production. Due to various reasons, the civil works at Vapi were affected. However, to avoid further delay in project implementation, the company acquired from SICOM an existing bulk drug unit with necessary infrastructure and production facilities at Lote Parashuram (near Ratnagiri).

Parent organization Indian Private
NSE symbol [-]
Founded 1987
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Bacil Pharma Ltd?

Answer Field

Bacil Pharma Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 36.36 as on Oct 30 2025 03:09 PM.

What is the Market Cap of Bacil Pharma Ltd Share?

Answer Field

The market cap of Bacil Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 52.20 as on Oct 30 2025 03:09 PM.

What is the 52 Week High and Low of Bacil Pharma Ltd?

Answer Field

The 52 Week High and Low of Bacil Pharma Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 62.56 and ₹ 31.59.

What is 1 year return for Bacil Pharma Ltd?

Answer Field

The 1 year returns on the stock has been -10.41%.

What is the P/E Ratio of Bacil Pharma Ltd Share?

Answer Field

As on Oct 30 2025 03:09 PM the price-to-earnings (PE) ratio for Bacil Pharma Ltd share is 49.70.

What is the PB ratio of Bacil Pharma Ltd Share?

Answer Field

As on Oct 30 2025 03:09 PM, the price-to-book (PB) ratio for Bacil Pharma Ltd share is 17.98.

How to Buy Bacil Pharma Ltd Share?

Answer Field

You can trade in Bacil Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Bacil Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Bacil Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Bacil Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59